Patents matching “ophthalmic”

US 12364680

Compounds for treating ophthalmic diseases and disorders

KIORA PHARMACEUTICALS GmbH · Granted Jul 22, 2025 · Expires Jul 17, 2045

US 12128036

Compositions and methods for storage stable ophthalmic drugs

LENZ THERAPEUTICS OPERATIONS, INC. · Granted Oct 29, 2024 · Expires Oct 24, 2044

US 12005139

Ophthalmic formulations and related methods

ETERNATEAR, INC. · Granted Jun 11, 2024 · Expires Jun 6, 2044

US 12005061

Ophthalmic formulations of methotrexate

Aldeyra Therapeutics, Inc. · Granted Jun 11, 2024 · Expires Jun 6, 2044

US 12005060

Ophthalmic formulations of methotrexate

Aldeyra Therapeutics, Inc. · Granted Jun 11, 2024 · Expires Jun 6, 2044

US 11964047

Ophthalmic formulations and related methods

ETERNATEAR, INC. · Granted Apr 23, 2024 · Expires Apr 18, 2044

US 11925686

Materials for phototherapies of ophthalmic diseases

EYEBRIGHT MEDICAL TECHNOLOGY (BEIJING) CO., LTD. · Granted Mar 12, 2024 · Expires Mar 7, 2044

US 11845989

Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors

REGENERON PHARMACEUTICALS, INC. · Granted Dec 19, 2023 · Expires Dec 14, 2043

US 11820982

Treatment of ophthalmic conditions with son of Sevenless 2 (SOS2) inhibitors

REGENERON PHARMACEUTICALS, INC. · Granted Nov 21, 2023 · Expires Nov 16, 2043

US 11786518

Ophthalmic formulations and uses thereof

Aldeyra Therapeutics, Inc. · Granted Oct 17, 2023 · Expires Oct 12, 2043

US 11767526

Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors

REGENERON PHARMACEUTICALS, INC. · Granted Sep 26, 2023 · Expires Sep 21, 2043

US 11752137

Ophthalmic compositions for treating ocular Demodex using lotilaner formulations

Tarsus Pharmaceuticals, Inc. · Granted Sep 12, 2023 · Expires Sep 7, 2043

US 11730716

Compounds for treating ophthalmic diseases and disorders

KIORA PHARMACEUTICALS GmbH · Granted Aug 22, 2023 · Expires Aug 17, 2043

US 11684570

Pharmaceutical ophthalmic compositions

EYE CARE NORTHWEST, PA · Granted Jun 27, 2023 · Expires Jun 22, 2043

US 11679078

Ophthalmic formulations and related methods

ETERNATEAR, INC. · Granted Jun 20, 2023 · Expires Jun 15, 2043

US 11679079

Ophthalmic formulations and related methods

ETERNATEAR, INC. · Granted Jun 20, 2023 · Expires Jun 15, 2043

US 11512309

Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors

REGENERON PHARMACEUTICALS, INC. · Granted Nov 29, 2022 · Expires Nov 24, 2042

CN 115348859

Ophthalmic formulations comprising n-[5-(aminosulfonyl)-4-methyl-1, 3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl) phenyl] acetamide hemihydrate

BAYER HEALTHCARE AG · Granted Nov 15, 2022 · Expires Nov 10, 2042

US 11439590

Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof

PYP CAR NORTHWEST, PA · Granted Sep 13, 2022 · Expires Sep 8, 2042

US 11285163

Ophthalmic solution

SENTISS PHARMA PRIVATE LIMITED · Granted Mar 29, 2022 · Expires Mar 24, 2042

US 11278493

Ophthalmic formulations providing durable ocular lubrication

ETERNATEAR, INC. · Granted Mar 22, 2022 · Expires Mar 17, 2042

US 10973871

Ophthalmic compositions

AURINIA PHARMACEUTICALS INC. · Granted Apr 13, 2021 · Expires Apr 8, 2041

US 10517869

Topical brimonidine tartrate ophthalmic solution

SENTISS PHARMA PRIVATE LIMITED · Granted Dec 31, 2019 · Expires Dec 26, 2039

US 10463674

Process for manufacturing sterile ophthalmic pharmaceutical suspensions

SENTISS PHARMA PRIVATE LIMITED · Granted Nov 5, 2019 · Expires Oct 31, 2039